Exelixis Inc (EXEL)
34.50
+0.29
(+0.85%)
USD |
NASDAQ |
Jan 08, 16:00
34.52
+0.02
(+0.06%)
After-Hours: 20:00
Exelixis Research and Development Expense (Annual): 1.044B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
Merck & Co Inc | 30.53B |
ADMA Biologics Inc | 3.30M |
Alnylam Pharmaceuticals Inc | 1.004B |
Incyte Corp | 1.628B |
Sarepta Therapeutics Inc | 877.39M |